{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:54:29Z","timestamp":1783997669239,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008038","name":"Neuromuscular Research Association Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.molimm.2022.08.018","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:19:11Z","timestamp":1662095951000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Complement and myasthenia gravis"],"prefix":"10.1016","volume":"151","author":[{"given":"Nicholas S.R.","family":"Sanderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.molimm.2022.08.018_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0197-0186(99)00154-0","article-title":"Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors","volume":"36","author":"Arias","year":"2000","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.molimm.2022.08.018_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.1971.tb30744.x","article-title":"Ultrastructural alterations in muscle from patients with myasthenia gravis and Eaton-Lumbert syndrome","volume":"183","author":"Bergman","year":"1971","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.molimm.2022.08.018_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2019-322640","article-title":"Myasthenia gravis AChR antibodies inhibit, function of rapsyn-clustered AChRs","volume":"91","author":"Cetin","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.molimm.2022.08.018_bib4","doi-asserted-by":"crossref","DOI":"10.1021\/bi00511a017","article-title":"Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor","author":"Conti-Tronconi","year":"1981","journal-title":"Biochemistry ."},{"issue":"6176","key":"10.1016\/j.molimm.2022.08.018_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.molimm.2022.08.018_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin. Neurol."},{"issue":"20","key":"10.1016\/j.molimm.2022.08.018_bib7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.molimm.2022.08.018_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.molimm.2022.08.018_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0034-2016","article-title":"Complement receptors in myeloid cell adhesion and phagocytosis","volume":"4","author":"Dustin","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.molimm.2022.08.018_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molimm.2022.08.018_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.1976.tb47676.x","article-title":"The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study","volume":"274","author":"Engel","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molimm.2022.08.018_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1981.tb33730.x","article-title":"The immunopathology of acquired myasthenia gravis","volume":"377","author":"Engel","year":"1981","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.molimm.2022.08.018_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"27","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.molimm.2022.08.018_bib14","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.molimm.2022.08.018_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14737159.2021.1927715","article-title":"Improving laboratory diagnostics in myasthenia gravis","volume":"21","author":"Gastaldi","year":"2021","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.molimm.2022.08.018_bib17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/(SICI)1097-4598(199707)20:7<800::AID-MUS3>3.0.CO;2-B","article-title":"Detection of antibody classes and subpopulations in myasthenia gravis patients using a new nonradioactive enzyme immunoassay","volume":"20","author":"Gotti","year":"1997","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.molimm.2022.08.018_bib18","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1073\/pnas.74.7.3090","article-title":"Modulation of acetylcholine receptor by antibody against the receptor","volume":"74","author":"Heinemann","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.molimm.2022.08.018_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.molimm.2022.08.018_bib20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, Placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.molimm.2022.08.018_bib21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, Placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann. Thorac. Surg."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1749-6632.2012.06783.x","article-title":"The role of complement in experimental autoimmune myasthenia gravis","volume":"1274","author":"Kusner","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Pt 7","key":"10.1016\/j.molimm.2022.08.018_bib25","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.molimm.2022.08.018_bib26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.39.8.1069","article-title":"Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis","volume":"39","author":"Lennon","year":"1989","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.molimm.2022.08.018_bib27","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/nyas.13550","article-title":"Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis","volume":"1413","author":"Luo","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.molimm.2022.08.018_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185976","article-title":"Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools","volume":"12","author":"Makino","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.molimm.2022.08.018_bib30","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.molimm.2022.08.018_bib31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/cells10020358","article-title":"The metabolic stability of the nicotinic acetylcholine receptor at the neuromuscular junction","volume":"10","author":"Martinez-Pena","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.molimm.2022.08.018_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"issue":"27","key":"10.1016\/j.molimm.2022.08.018_bib33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"41","key":"10.1016\/j.molimm.2022.08.018_bib34","doi-asserted-by":"crossref","first-page":"29977","DOI":"10.1074\/jbc.M703742200","article-title":"Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex","volume":"282","author":"Moskovich","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molimm.2022.08.018_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis\u2013specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molimm.2022.08.018_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211001995","article-title":"Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance","volume":"14","author":"Murai","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.molimm.2022.08.018_bib38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.molimm.2022.08.018_bib39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.molimm.2022.08.018_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114168","article-title":"Snake three-finger \u03b1-neurotoxins and nicotinic acetylcholine receptors: molecules, mechanisms and medicine","volume":"181","author":"Nirthanan","year":"2020","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.molimm.2022.08.018_bib41","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23043","article-title":"Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications","volume":"6","author":"Noridomi","year":"2017","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.molimm.2022.08.018_bib42","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001169","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol Neuroimmunol. Neuroinflamm."},{"issue":"17","key":"10.1016\/j.molimm.2022.08.018_bib43","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.molimm.2022.08.018_bib44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2022.08.018_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2022.109551","article-title":"A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies","volume":"373","author":"Plomp","year":"2022","journal-title":"J. Neurosci. Methods"},{"issue":"4","key":"10.1016\/j.molimm.2022.08.018_bib46","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1152\/physrev.1984.64.4.1162","article-title":"Nicotinic receptor of acetylcholine: structure of an oligomeric integral membrane protein","volume":"64","author":"Popot","year":"1984","journal-title":"Physiol. Rev."},{"issue":"12","key":"10.1016\/j.molimm.2022.08.018_bib47","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.73.12.4584","article-title":"Studies of human myasthenia gravis: electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylcholine receptor complex","volume":"73","author":"Rash","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13075-021-02609-5","article-title":"Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load","volume":"23","author":"Reijm","year":"2021","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.molimm.2022.08.018_bib49","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molimm.2022.08.018_bib50","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1749-6632.1981.tb33758.x","article-title":"Intercostal muscle biopsy studies in myasthenia gravis: clinical correlations and the direct effects of drugs and myasthenic serum","volume":"377","author":"Sanders","year":"1981","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"24","key":"10.1016\/j.molimm.2022.08.018_bib51","doi-asserted-by":"crossref","first-page":"11900","DOI":"10.1073\/pnas.1901841116","article-title":"Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b","volume":"116","author":"Sharp","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.molimm.2022.08.018_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41565-018-0336-3","article-title":"Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies","volume":"14","author":"Shaw","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.molimm.2022.08.018_bib53","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.molimm.2022.08.018_bib54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0896-8411(89)90004-8","article-title":"Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera","volume":"2","author":"Sophianos","year":"1989","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.molimm.2022.08.018_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0165-5728(01)00401-5","article-title":"Myocytes respond in vivo to an antibody reactive with the acetylcholine receptor by upregulating interleukin-15: an interferon-gamma activator with the potential to influence the severity and course of experimental myasthenia gravis","volume":"119","author":"Stegall","year":"2001","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.molimm.2022.08.018_bib56","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acs.nanolett.9b02220","article-title":"Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces","volume":"19","author":"Strasser","year":"2019","journal-title":"Nano Lett."},{"issue":"3","key":"10.1016\/j.molimm.2022.08.018_bib57","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.molimm.2022.08.018_bib58","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1212\/WNL.39.10.1359","article-title":"Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis","volume":"39","author":"Tsujihata","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0014-5793(86)80220-4","article-title":"Decrease in acetylcholine-receptor content of human myotube cultures mediated by monoclonal antibodies to alpha, beta and gamma subunits","volume":"196","author":"Tzartos","year":"1986","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.molimm.2022.08.018_bib60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molimm.2022.08.018_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molimm.2022.08.018_bib62","article-title":"PMID: 15701510 J Mol Biol 2005 Mar 4;346(4):967-89. doi: 10.1016\/j.jmb.2004.12.031. Epub 2005 Jan 25.","author":"Unwin","year":"2005","journal-title":"Refined structure of the nicotinic acetylcholine receptor at 4A resolution"},{"issue":"2","key":"10.1016\/j.molimm.2022.08.018_bib63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"Muscle Nerve"},{"issue":"349","key":"10.1016\/j.molimm.2022.08.018_bib64","article-title":"Severe worsening of myasthenic symptoms after the eculizumab discontinuation","volume":"15","author":"Uzawa","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.molimm.2022.08.018_bib65","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.molimm.2022.08.018_bib66","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","article-title":"Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets","volume":"190","author":"Xie","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molimm.2022.08.018_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2019.105630","article-title":"Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy","volume":"189","author":"Yanagidaira","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"8","key":"10.1016\/j.molimm.2022.08.018_bib68","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.neuron.2022.01.013","article-title":"Conformational transitions and ligand-binding to a muscle-type nicotinic acetylcholine receptor","volume":"110","author":"Zarkadas","year":"2022","journal-title":"Neuron"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016158902200414X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016158902200414X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:43:27Z","timestamp":1758980607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016158902200414X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":68,"alternative-id":["S016158902200414X"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2022.08.018","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement and myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2022.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}